Utilization of pumpkin, pumpkin powders, extracts, isolates, purified bioactives and pumpkin based functional food products: A key strategy to improve health in current post COVID 19 period: An updated review.

Progression of today's world has been given setback due to the adversity of a novel, viral and deadly outbreak COVID 19, which raised the concerns of the scientists, researchers and health related officials about the inherent and adaptive immune system of the living body and its relation with healthy diet balanced with pharma foods. Choice of right food can help to build and boost adaptive immunity and pumpkin due to excellent profile of functional and nutraceutical constituents must be the part of both infected and non-infected person's daily diet. Vitamins, minerals, phenolic acids, essential oils, peptides, carotenoids and polysaccharides present in pumpkin could accommodate the prevailing deficiencies in the body to fought against the pathogens. Pumpkins are well equipped with nutraceuticals and functional ingredients therefore, consumption and processing of this remarkable fruit must be encouraged as pharma food due to its antihyperlipidemic, antiviral, anti-inflammatory, antihyperglycemic, immunomodulatory, antihypertensive, antimicrobial and antioxidant potential, and these pharmacological properties of pumpkin are directly or indirectly related to the COVID 19 outbreak. Utilization of pumpkin has a domain in the form of powders, extracts, isolates, and pumpkin incorporated food products. A wide range of healthy, nutritious and functional food products has been developed from pumpkin, which includes juice, soup, porridge, chips, biscuits, bread, cake, bar and noodles. In recent times some innovative and novel technologies have been applied to process and preserve pumpkin for its enhanced shelf life and bioaccessibility of nutrients. Need of healthy eating in current post COVID 19 period is very crucial for healthy population, and medicinal foods like pumpkin, and bioactive compounds present in this functional food could play a vital role in developing a healthy community around the globe.

Advances in viral oncolytics for treatment of multiple myeloma - a focused review.

INTRODUCTION: Oncolytic viruses are genetically engineered viruses that target myeloma-affected cells by detecting specific cell surface receptors (CD46, CD138), causing cell death by activating the signaling pathway to induce apoptosis or by immune-mediated cellular destruction. AREAS COVERED: This article summarizes oncolytic virotherapy advancements such as the therapeutic use of viruses by targeting cell surface proteins of myeloma cells as well as the carriers to deliver viruses to the target tissues safely. The major classes of viruses that have been studied for this include measles, myxoma, adenovirus, reovirus, vaccinia, vesicular-stomatitis virus, coxsackie, and others. The measles virus acts as oncolytic viral therapy by binding to the CD46 receptors on the myeloma cells to utilize its surface H protein. These H-protein and CD46 interactions lead to cellular syncytia formation resulting in cellular apoptosis. Vesicular-stomatitis virus acts by downregulation of anti-apoptotic factors (Mcl-2, BCL-2). Based upon the published literature searches till December 2020, we have summarized the data supporting the advances in viral oncolytic for the treatment of MM. EXPERT OPINION: Oncolytic virotherapy is an experimental approach in multiple myeloma (MM); many issues need to be addressed for safe viral delivery to the target tissue.

Atypical Case of COVID-19 Associated Kawasaki Disease in an Eight-Year-Old Pakistani Boy.

People of all age groups have been affected worldwide during the coronavirus disease 2019 (COVID-19) pandemic. While the global efforts of researchers, clinicians, and scientists are underway, cases involving multiple systems with a wide range of presentations are on the horizon. As health organizations have started warnings about unusual manifestations of a Kawasaki disease (KD)-like inflammatory syndrome associated with COVID-19, some pediatric cardiologists noted that even classic cases are likely going undercounted. Here we report a case of a previously healthy eight-year-old Pakistani boy who presented with a four-day history of low-grade fever. The patient was admitted and diagnosed with COVID-19-associated atypical KD in the setting of fever for more than five days, maculopapular eruptions, and mild conjunctivitis. He screened positive for COVID-19 with an immunoglobulin G titer of 2.1 plus ruling out other childhood illnesses. He was managed with intravenous immunoglobulins and aspirin with gradual resolution of symptoms. His initial echocardiogram was unremarkable. He was discharged home on day six with a follow-up at two weeks.

The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts.

The whole world is concerned about the pandemic of coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), due to fatality of this condition. This has become a public health emergency of international concern. No specific vaccine and medicine have proven effective in large-sized trials at this time. With the rapidly increasing number of positive cases and deaths, there is a dire need for effective treatments and an effective vaccine for prevention. An urgent unmet need led to the planning and opening of multiple drug development trials for treatment and vaccine development. In this article, we have summarized data on cell receptor interactions and data on prospects of new vaccines targeting the deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA), and viral minigenes. We have tabulated the available data on various clinical trials testing various aspects of COVID-19 vaccines.

Nanoantibiotics: Future nanotechnologies to combat antibiotic resistance.

The discovery of antibiotics was hailed as a historic breakthrough for the human race in the fight against bacterial and malignant infections. However, in a very short time, owing to their acute and aggressive nature, bacteria have developed resistance against antibiotics and other chemotherapeutics agents. Potentially, this situation could again result in bacterial infection outbreaks. Metal and metal oxide nanoparticles have been proven as better alternatives; the combination of antibiotics and metal oxide nanoparticles was shown to decrease the toxicity and enhance the antibacterial, antiviral, and anticancer efficacy of the agents. This review provides a detailed view about the role of metal and metal oxide nanoparticles in the treatment of infections in conjunction with antibiotics, their modes of action, and synergism. In addition, the problems of multidrug resistance are addressed and will allow the development of a comprehensive, reliable, and rational treatment plan. It is expected that this comprehensive review will lead to new research opportunities, which should be helpful for future applications in biomedical science.